Suppr超能文献

垂体腺瘤放疗的长期随访:4500 cGy及以上剂量放疗后无晚期复发

Long-term follow-up of radiotherapy for pituitary adenoma: the absence of late recurrence after greater than or equal to 4500 cGy.

作者信息

McCollough W M, Marcus R B, Rhoton A L, Ballinger W E, Million R R

机构信息

Dept. of Radiation Oncology, University of Florida College of Medicine, Gainesville.

出版信息

Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):607-14. doi: 10.1016/0360-3016(91)90677-v.

Abstract

Recent literature has suggested that late recurrence of pituitary adenoma after radiotherapy is common. We hypothesized that late failures might be a result of inadequate dose (less than 4500 cGy). To investigate, we analyzed 105 patients treated at our institution between 1965 and 1986 (analysis, 2/89). The minimum observation time was greater than or equal to 5 years in 58% and greater than or equal to 10 years in 30% of the patients. All patients received megavoltage radiotherapy (range, 4200-5500 cGy; mean, 4821 cGy) at a mean dose per fraction of 172 cGy; 100 patients received greater than or equal to 4500 cGy tumor dose. Twenty-nine patients received radiotherapy alone, and 76 had postoperative radiotherapy after frontal craniotomy (20 patients) or transsphenoidal hypophysectomy (56 patients). At presentation, 71% of patients had extrasellar disease, 57% had visual field deficits, and 50% had endocrinopathy. Of patients treated postoperatively, 74% had gross residual disease. Four local failures occurred at 13, 16, 57, and 64 months after postoperative radiotherapy, all within the irradiated volume (tumor doses of 4700, 4715, 5000, and 5100 cGy). All four patients had presented with moderate to extensive extrasellar disease with visual field defects. Two of the four remain free of second recurrence at 7 and 13 years after salvage transsphenoidal hypophysectomy. The local control rate with radiotherapy (product-limit method) at 10 years was 100% in the radiotherapy-alone group and 92% in the postoperative radiotherapy group (95% for all patients). To prevent bias, seven patients who received bromocriptine, none of whom demonstrated a recurrence, were censored from the local control analysis at the initiation of the drug. No patient in this study suffered recurrence greater than 64 months after radiotherapy, with 31 patients (none with bromocriptine) observed 10 to 21 years. We conclude that treatment of pituitary adenoma with greater than or equal to 4500 cGy in 25 fractions can result in a high (greater than or equal to 90%) probability of stable long-term control.

摘要

近期文献表明,垂体腺瘤放疗后晚期复发很常见。我们推测晚期放疗失败可能是由于剂量不足(小于4500 cGy)。为进行研究,我们分析了1965年至1986年间在我院接受治疗的105例患者(分析时间为1989年2月)。58%的患者最短观察时间大于或等于5年,30%的患者大于或等于10年。所有患者均接受兆伏级放疗(范围4200 - 5500 cGy;平均4821 cGy),每次分割的平均剂量为172 cGy;100例患者肿瘤剂量大于或等于4500 cGy。29例患者仅接受放疗,76例患者在经额开颅手术(20例)或经蝶窦垂体切除术(56例)后接受术后放疗。就诊时,71%的患者有鞍外病变,57%有视野缺损,50%有内分泌病。术后接受治疗的患者中,74%有肉眼可见的残留病灶。术后放疗后13、16、57和64个月出现4例局部放疗失败,均在照射野内(肿瘤剂量分别为4700、4715、5000和5100 cGy)。这4例患者就诊时均有中度至广泛的鞍外病变伴视野缺损。4例中的2例在挽救性经蝶窦垂体切除术后7年和13年未出现二次复发。放疗组10年的局部控制率(乘积限法),单纯放疗组为100%,术后放疗组为92%(所有患者为95%)。为避免偏差,7例接受溴隐亭治疗且均未复发的患者在开始用药时从局部控制分析中剔除。本研究中无患者在放疗后64个月以上出现复发,31例患者(均未用溴隐亭)观察了10至21年。我们得出结论,垂体腺瘤采用25次分割、剂量大于或等于4500 cGy的治疗可使长期稳定控制的概率很高(大于或等于90%)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验